cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Alliance formed to develop melanoma product MDX-010
December 14th, 2004
Bristol-Myers Squibb Company (BMY) and Medarex, Inc., (MEDX) announced a worldwide collaboration to develop and commercialize MDX-010, a fully human antibody investigational product targeting the CTLA-4 receptor. MDX-010 was developed by Medarex using its UltiMAb Human Antibody Development System and is currently in phase III clinical development for the treatment of metastatic melanoma. There are more than 160,000 cases of melanoma diagnosed worldwide, and 40,000 annual deaths. The agreement is subject to receipt of various governmental clearances and approvals, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of...
Source: cancer weekly (2004-12-14)
|
